Luoxin Anruoweita Pharmaceutical

Luoxin Anruoweita Pharmaceutical is a specialized subsidiary of the Shandong Luoxin Pharmaceutical Group, focused on the research, development, and commercialization of innovative therapeutic agents in China. The company primarily targets high-incidence diseases in oncology and gastroenterology, utilizing a robust pipeline of small molecule candidates. Its lead commercial product, Tegoprazan, is a first-in-class potassium-competitive acid blocker (P-CAB) in China, reflecting the company's strength in digestive health. Through strategic collaborations and internal R&D, Luoxin Anruoweita aims to address significant unmet medical needs by transitioning from a traditional generic manufacturer to an innovation-driven biopharmaceutical player. The entity represents a strategic bridge for global innovative assets entering the Chinese market.